Irinotekan Teva (Irinotecan Hydrochloride Trihydrate)

Irinotecan is a pro‑drug that is converted inside tumor cells to SN‑38, an active metabolite that binds to the DNA‑topoisomerase I complex. This binding prevents the enzyme from resealing DNA strands during replication, causing DNA damage and ultimately leading to cancer cell death.

The specific dose of Irinotekan is determined by the prescribing oncologist based on factors such as body surface area, disease stage, and patient tolerance. Dosing regimens are individualized and should follow the clinician’s written order.

The safety of irinotecan in pregnancy and lactation has not been established. It is generally contraindicated because of potential fetal toxicity and the possibility of drug excretion in breast milk. Women of child‑bearing potential should use effective contraception during treatment.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed), and import documentation.

Irinotecan belongs to the topoisomerase I inhibitor class, differing from agents such as oxaliplatin (a platinum compound) or fluoropyrimidines. It is often combined with 5‑fluorouracil and leucovorin (FOLFIRI regimen) and offers a distinct mechanism that can be effective in patients who have progressed on other chemotherapy backbones.

Irinotekan should be stored refrigerated at 2‑8 °C, protected from light, and must not be frozen or shaken. The product should be kept in its original container until preparation for infusion, and any unused portion should be discarded according to local regulations.

Irinotekan is supplied as a sterile intravenous solution. It is administered by slow infusion through a peripheral or central line, typically over 30‑90 minutes, according to the prescribing physician’s protocol and under close clinical supervision.

The most serious adverse events include severe neutropenia with fever (febrile neutropenia), life‑threatening diarrhea or colitis, and hypersensitivity reactions such as anaphylaxis. Prompt monitoring and supportive care are essential to manage these risks.

Patients with known hypersensitivity to irinotecan or any component of the formulation should avoid the drug. It is also contraindicated in individuals with recent bowel obstruction, severe hepatic impairment, or uncontrolled infections, and caution is advised for those with pre‑existing bone‑marrow suppression.